Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 15, Issue 10, 1997, Pages 3171-3177

  Rahman, Zia U ^a   Frye, Debra K ^a   Buzdar, Aman U ^a   Smith, Terry L ^a   Asmar, Lina ^a   Champlin, Richard E ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTINEOPLASTIC AGENT; BCG VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; IFOSFAMIDE; METHOTREXATE; MITOLACTOL; PEPTICHEMIO; TAMOXIFEN; THIOTEPA; VINCRISTINE;

ADULT; ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL;

EID: 0030983888     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.10.3171     Document Type: Article

References (29)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:71-85, 1992
2. Antman KS, Armitage JO, Horowitz MM, et al: Autotransplants for breast cancer in North America. Proc Annu Meet Am Soc Clin Oncol 13:A69 1994 (Abstr)
3. Teicher BA, Holden SA, Cucchi CA, et al: Combination thiotepa and cyclophosphamide in vivo and in vitro. Cancer Res 48:94-100, 1988
4. Skipper HE, Schabel FM: Quantitative and cytokinetic studies in experimental tumor systems, in: Holand J, Frei E (eds): Cancer Medicine. Philadelphia PA, Lea & Febiger, 1982, pp 663-684
5. Hryniuk W, Levine MN: Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 4:1162-1170, 1986
6. Hryniuk W, Bush H: The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 2:1281-1288, 1984
7. Tannock IF, Boyd NF, Deboer F, et al: A randomized trial of two dose levels of cyclophosphamide, methotrexate and fluorouracil chemotherapy for patients with metastatic breast cancer. J Clin Oncol 6:1377-1387, 1988
8. Jones RB, Holland JF, Bhardwal S, et al: A phase I-II study of intensive-dose adriamycin for advanced breast cancer. J Clin Oncol 5:172-177, 1987
9. Peters WP: Advances in the supportive care of patients receiving high-dose chemotherapy and autologous bone marrow transplantation for breast cancer. Supportive Care in Cancer, 4th International Symposium, February 1993, pp 24-27 (abstr)
10. Wallerstein R, Jr., Spitzer G, Dunphy F, et al: A phase II study of mitoxantrone, etoposide, and thiotepa with autologous marrow support for patients with relapsed breast cancer. J Clin Oncol 8:1782-1788, 1990
11. Shea T, Graham M, Steagall A, et al: Multiple cycles of high dose taxol plus carboplatin with G-CSF (filgrastim) and peripheral blood progenitor cell (PBPC) support. Proc Annu Meet Am Soc Clin Oncol 13:A395, 1994 (abstr)
12. Antman K, Eder JP, Elias A, et al: High-dose combination alkylating agent preparative regimen with autologous bone marrow support: The Dana-Farber Cnacer Institute/Beth Israel hospital experience. Cancer Treat Rep 71:119-125, 1987
13. Peters WP, Shpall EJ, Jones RB, et al: High dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol 6:1368-1376, 1988
14. Dunphy FR, Spitzer G, Buzdar AU, et al: Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol 8:1207-1216, 1990
15. Smith GA, Henderson IC: High-dose chemotherapy (HDC) with autologous bone marrow transplantation (ABMT) for the treatment of breast cancer: The jury is still out. Important Adv Oncol 201-214, 1995
16. Mulder NH, Dolsma WV, Mulder PO, et al: Long-term results of induction and intensification chemotherapy supported with autologous bone marrow reinfusion in patients with disseminated or T4 breast cancer. Anticancer Res 15:1565-1568, 1995
17. Dunphy FR, Spitzer G, Fornoff JE, et al: Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support [published erratum appears in Cancer, 74:773, 1994]. Cancer 73:2157-2167, 1994
18. Bezwoda WR, Seymour L, Dansey RD: High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 13:2483-2489, 1995
19. Peters W, Jones R, Vredenburgh J, et al: A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Breast Cancer Res Treatment 37:35, 1996
20. Hortobagyi GN, Smith TL, Legha SS, et al: Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1:776-786, 1983
21. Swenerton KD, Legha SS, Smith T, et al: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552-1562, 1979
22. Zubrod CG, Schneiderman M, Frei I, et al: Appraisal of methods for the study of chemotherapy of cancer in man: Comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. Cancer 11:7-33, 1960
23. Antman K, Ayash L, Elias A, et al: A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 10:102-110, 1992
24. Peters WP, Jones RB, Vredenburgh J, et al: A large, prospective, randomized trial of high-dose combination alkylating agents (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc Annu Meet Am Soc Clin Oncol 96; 15:A149, 1996 (abstr)
25. Rowlings PA, Antman KS, Horowitz MM, et al: Prognostic factors in autotransplants for breast cancer. Proc Annu Meet Am Soc Clin Oncol 14:A966, 1995 (abstr)
26. Ayash LJ, Wheeler C, Fairclough D, et al: Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 13:2043-2049, 1995
27. Buzdar AU, Legha SS, Hortobagyi GN, et al: Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. Cancer 47:2798-2802, 1981
28. Hortobagyi GN, Bodey GP, Buzdar AU, et al: Evaluation of high-dose versus standard FAC chemotherapy for advanced breast cancer in protected environment units: A prospective randomized study. J Clin Oncol 5:354-364, 1987
29. Bezwoda WR, Dansey R, Seymour L: First-line chemotherapy of advanced breast cancer with mitoxantrone, cyclophosphamide and vincristine. Oncology 46:208-211, 1989